A 26-week Primary Treatment Phase, with 26-week Extension,
Open-label, Randomized Clinical Trial Evaluating the Efficacy and
Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections,
Both in Combination with a Basal Insulin, in Pediatric Subjects with
Type 1 or Type 2 Diabetes Mellitus
Please contact us for more information or to learn if you are eligible to participate.
